Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease

Kidney International

Volumn 86, Issue 6, 2014, Pages 1213-1220

  Yilmaz, Mahmut I ^a   Siriopol, Dimitrie ^b   Saglam, Mutlu ^a   Kurt, Yasemin G ^a   Unal, Hilmi U ^a   Eyileten, Tayfun ^a   Gok, Mahmut ^a   Cetinkaya, Hakki ^a   Oguz, Yusuf ^a   Sari, Sebahattin ^a   Vural, Abdulgaffar ^a   Mititiuc, Irina ^b   Covic, Adrian ^b   Kanbay, Mehmet ^c  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

Author keywords

Cardiovascular disease; Chronic kidney disease; Endocan; Inflammation

Indexed keywords

C REACTIVE PROTEIN; ENDOCAN; PENTRAXIN 3; PROTEOGLYCAN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; ESM1 PROTEIN, HUMAN; SERUM AMYLOID P; TUMOR PROTEIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FLOW MEDIATED VASODILATATION; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL; VASCULAR DISEASE; VASODILATATION; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; METABOLISM; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; BIOMARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROPORTIONAL HAZARDS MODELS; PROTEOGLYCANS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SERUM AMYLOID P-COMPONENT; VASODILATION;

EID: 84926167129     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.227     Document Type: Article

References (48)

1. Stenvinkel P. Chronic kidney disease: A public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010; 268: 456-467.
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. Vanholder R, Massy Z, Argiles A et al. European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056.
4. Shulman NB, Ford CE, Hall WD et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989; 13(5 Suppl): I80-I93.
5. Sarnak MJ, Levey AS, Schoolwerth AC et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
6. Delehedde M, Devenyns L, Maurage C-A et al. Endocan in cancers: A lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol 2013; 2013: 705027.
7. Scherpereel A, Depontieu F, Grigoriu B et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006; 34: 532-537.
8. Grigoriu BD, Depontieu F, Scherpereel A et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006; 12: 4575-4582.
9. Maurage CA, Adam E, Mineó JF et al. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol 2009; 68: 633-641.
10. Kim JH, Park MY, Kim CN et al. Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1a in human colon carcinoma: impact of ESM-1 on prognosis and its correlation with clinicopathological features. Oncol Rep 2012; 28: 1701-1708.
11. Zhang SM, Zuo L, Zhou Q et al. Expression and distribution of endocan in human tissues. Biotech Histochem 2012; 87: 172-178.
12. Sarnak MJ, Levey AS. Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. J Thromb Thrombolysis 2000; 10: 169-180.
13. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9(Suppl): S16-S23.
14. Ley K, Laudanna C, Cybulsky MI et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678-689.
15. Attalah MF, Adel LA, Fahmy DE. Diagnostic and prognostic values of adhesion molecules VCAM-1, ICAM-1 and C-reactive protein in Egyptian patients with chronic kidney disease. Egypt J Immunol 2011; 18: 59-66.
16. Caballo C, Palomo M, Cases A et al. NFkB in the development of endothelial activation and damage in uremia: An in vitro approach. PLoS One 2012; 7: e43374.
17. Tumur Z, Shimizu H, Enomoto A et al. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am J Nephrol. 2010; 31: 435-441.
18. Béchard D, Scherpereel A, Hammad H et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001; 167: 3099-3106.
19. Abid MR, Yi X, Yano K et al. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 2006; 72: 136-145.
20. Chen YT, Cheng BC, Ko SF et al. Value and level of circulating endothelial progenitor cells, angiogenesis factors and mononuclear cell apoptosis in patients with chronic kidney disease. Clin Exp Nephrol 2013; 17: 83-91.
21. Verma S, Li SH, Wang CH et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-740.
22. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: A metaanalysis. Int J Cardiovasc Imaging 2010; 26: 631-640.
23. Frick M, Suessenbacher A, Alber HF et al. Prognostic value of brachial artery endothelial function and wall thickness. J Am Coll Cardiol 2005; 46: 1006-1010.
24. Polak JF, Pencina MJ, Pencina KM et al. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011; 365: 213-221.
25. Szeto CC, Chow KM, Woo KS et al. Carotid intima media thickness predicts cardiovascular diseases in Chinese predialysis patients with chronic kidney disease. J Am Soc Nephrol 2007; 18: 1966-1972.
26. Banerjee D, Recio-Mayoral A, Chitalia N et al. Insulin resistance, inflammation, and vascular disease in nondiabetic predialysis chronic kidney disease patients. Clin Cardiol 2011; 34: 360-5.27.
27. Recio-Mayoral A, Banerjee D, Streather C et al. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease-a crosssectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis 2011; 216: 446-451.
28. Ghanavatian S, My Diep L, Bárány P et al. Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4. Angiology 2013; 65: 443-449.
29. Oltean S, Pullerits R, Flodén A et al. Increased resistin in brain dead organ donors is associated with delayed graft function after kidney transplantation. J Transl Med 2013; 11: 30.
30. Balta S, Mikhailidis DP, Demirkol S et al. Endocan-a novel inflammatory indicator in newly diagnosed patients with hypertension: A pilot study. Angiology 2014 (Epub ahead of print).
31. Filková M1, Haluzík M, Gay S et al. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol 2009; 133: 157-170.
32. Schwarz C, Regele H, Steininger R et al. The contribution of adhesion molecule expression in donor kidney biopsies to early allograft dysfunction. Transplantation 2001; 71: 1666-1670.
33. Stenvinkel P. New insights on inflammation in chronic kidney diseasegenetic and non-genetic factors. Nephrol Ther 2006; 2: 111-119.34.
34. Tong M, Carrero JJ, Qureshi AR et al. Plasma pentraxin 3 in patients with chronic kidney disease: Associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007; 2: 889-897.
35. Suliman ME, Yilmaz MI, Carrero JJ et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 976-985.
36. Busch M, Franke S, Mü ller A et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004; 66: 338-347.
37. Boehme M, Kaehne F, Kuehne A et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant 2007; 22: 2224-2229.
38. Stenvinkel P, Heimbü rger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911.
39. Balta I, Balta S, Koryurek OM et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol 2014; 70: 291-296.
40. Fazzini F, Peri G, Doni A et al. PTX3 in small-vessel vasculitides: An independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001; 44: 2841-2850.
41. Yilmaz MI, Stenvinkel P, Sonmez A et al. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant 2011; 26: 3537-3543.
42. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1-201.
43. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
44. Yilmaz MI, Sonmez A, Ortiz A et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol 2011; 6: 785-792.
45. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
46. Corretti MC, Anderson TJ, Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
47. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843.
48. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.